Daré Bioscience (NASDAQ:DARE) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report published on Friday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Trading Down 10.0 %

NASDAQ:DARE traded down $0.36 on Friday, reaching $3.21. 103,013 shares of the stock traded hands, compared to its average volume of 47,472. The company’s 50 day moving average is $3.56 and its 200-day moving average is $3.92. Daré Bioscience has a 1-year low of $3.05 and a 1-year high of $7.56. The firm has a market capitalization of $27.45 million, a price-to-earnings ratio of -2.86 and a beta of 1.34.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC lifted its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.